In a recent clinical trial, CRISPR gene editing was applied to 14 patients suffering from a form of inherited blindness. The treatment proved safe and resulted in measurable vision improvements in 11 of the participants. The trial, named BRILLIANCE, signifies a significant step forward in gene therapy for ocular diseases